
About Aspira Diagnostics
Aspira Diagnostics is a publicly listed company based in Mumbai (India) founded in 2015. Pathology lab services are operated through a chain of facilities. The company has 70 employees. Its chief executive, as recorded, is Chander Puri. Its Indian entity Aspira Pathlab & Diagnostics Limited reported revenue of ₹25.50 Cr. Aspira Diagnostics offers products and services including Pathology Test, Sonography, X-Ray, and Health Packages. Its focus areas include Clinical Laboratory Chains and Pathology. Similar companies include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics; 3 of its 3 listed similar companies have raised funding.
Company details
Aspira was founded in 2015 and is based in Mumbai, India. The company operates as a chain of pathology labs focused on diagnostic services. Core activities include laboratory testing and pathology diagnostics, with operations centered in the healthcare sector. The domain aspiradiagnostics.com is used for its online presence. Leadership is provided by CEO Chander Puri.
- Headquarters Mumbai, India
- Employees 70
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website aspiradiagnostics.com
- Social LinkedIn X Facebook Instagram
- Legal Name Aspira Pathlab & Diagnostics Ltd.
- Market Cap₹135 Cr
ASPIRA · BSE
- Share Price₹137.55
+5.00% today
- Revenue₹22.00 Cr
FY 2024-25 · +66.7% YoY
- EBITDA₹3.47 Cr
Margin 15.8%
- Net Profit₹2.05 Cr
FY 2024-25 · +176.2% YoY
- P/E (TTM)55.4x
P/B 18.4x
- ROE16.5%
ROCE 11.5%
- Debt / Equity0.15
Interest cover 17.7x
- Latest Funding Round$401.26K (USD), Post-IPO
Nov 2019
- Employee Count70
Associated legal entities of Aspira Diagnostics
Aspira Diagnostics operates through Aspira Pathlab & Diagnostics Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Aspira Pathlab & Diagnostics Limited Listed CIN L85100MH1973PLC289209 | Active | 03 Jul 1973 | Mumbai, Maharashtra | ₹25.5 Cr | 70 | 10 | View details |
Products & Services of Aspira Diagnostics
Aspira Diagnostics offers a comprehensive portfolio of products and services, including Pathology Test, Sonography, X-Ray, and Health Packages.
Laboratory analysis of blood and samples for health diagnosis
Ultrasound scans for detecting internal medical conditions
Radiographic exams for bone and tissue evaluation
Predefined tests for profiles like fever or monsoon-related issues
Funding Insights of Aspira Diagnostics
- Total Rounds 1
- Last Round Post-IPO — $401,258
- First Round $401,258
(Nov 2019)
All 1 funding rounds of Aspira Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2019 | $401,258 | Post-IPO | – | – | – |
Board of directors of Aspira Pathlab & Diagnostics Limited (Aspira Diagnostics)
Aspira Pathlab & Diagnostics Limited is the primary company behind Aspira Diagnostics. The board of Aspira Pathlab & Diagnostics Limited currently have 7 directors; the longest-serving is Pankaj Jashwant Shah, appointed in 2016. 25 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Pankaj Jashwant Shah DIN 02836324 | Managing Director | 01 Aug 2016 | 10 yrs 3 mo | Aspira Pathlab & Diagnostics Limited |
| Avinash Chander Mahajan DIN 00041661 | Director | 01 Feb 2017 | 9 yrs 9 mo | Aspira Pathlab & Diagnostics Limited |
| Haseeb Ahmad Drabu DIN 00489888 | Director | 27 Oct 2018 | 8 yrs | Aspira Pathlab & Diagnostics Limited |
| Nikunj Velji Mange DIN 08489442 | Director | 29 Aug 2020 | 6 yrs 2 mo | Aspira Pathlab & Diagnostics Limited |
| Manas Rajendra Mengar DIN 10218206 | Director | 12 Aug 2023 | 3 yrs 3 mo | Aspira Pathlab & Diagnostics Limited |
| Kiran Raghavendra Awasthi DIN 09066721 | Director | 12 Nov 2025 | 1 yr | Aspira Pathlab & Diagnostics Limited |
| Vaibhav Odhekar DIN 05135001 | Additional Director | 23 May 2026 | 5 mo | Aspira Pathlab & Diagnostics Limited |
People of Aspira Diagnostics
1 people are tracked at Aspira Diagnostics (1 in leadership); the tracked headcount is 70.
| Name | Role | Group |
|---|---|---|
| CEO | Leadership |
Complete people profiles for Aspira Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aspira Diagnostics
Aspira Diagnostics is a publicly listed company on the BSE with ticker symbol ASPIRA in India, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 May 2017
- Listed onBSE: 540788
- Listed entityAspira Pathlab & Diagnostics Ltd.
- Exchange sectorHealth services
- ISININE500C01017
- Share price₹120.40 (+4.97% on the day) · 2026-10-14
- Market capitalisation₹118 Cr
- Price to earnings21.1
- EPS (diluted, trailing year)₹-0.44
- Volume (last session)1,301
Financials of Aspira Diagnostics
Exchange-reported figures of Aspira Pathlab & Diagnostics Limited, the listed company behind Aspira Diagnostics (BSE: ASPIRA).
Financial Highlights
FY 2024-25 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Income statement | ||
| Revenue | 22.00 | 13.20 |
| Revenue growth | +66.7% | - |
| EBITDA | 3.47 | (1.20) |
| EBITDA margin | +15.8% | -9.1% |
| Profit before tax | 2.02 | (2.69) |
| Net profit | 2.05 | (2.69) |
| Net profit margin | +9.3% | -20.4% |
| EPS (₹) | 1.97 | (2.60) |
| Balance sheet | ||
| Total assets | 15.92 | 13.34 |
| Net worth | 13.37 | 11.22 |
| Total debt | 1.99 | 1.70 |
| Cash & bank | 2.14 | 1.38 |
| Net working capital | 3.81 | 2.98 |
| Cash flow | ||
| Cash from operations | 1.83 | 1.05 |
| Cash from investing | 0.12 | 0.14 |
| Cash from financing | (0.99) | (0.95) |
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Jun 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.25 | 5.78 | 5.41 | 6.18 | 4.64 | 3.82 | 2.60 |
| Revenue growth (YoY) | +13.2% | +51.3% | - | - | +78.5% | - | - |
| Other income | 0.11 | 0.13 | 0.09 | 0.08 | 0.16 | 0.08 | 0.10 |
| EBITDA | 0.68 | 0.92 | 0.61 | 1.28 | 0.27 | (0.20) | (0.43) |
| EBITDA margin | +13.0% | +15.9% | +11.3% | +20.7% | +5.8% | -5.2% | -16.5% |
| Depreciation | 0.37 | 0.37 | 0.39 | 0.36 | 0.38 | 0.38 | 0.39 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| EPS (₹) | 0.41 | 0.66 | 0.30 | 0.96 | 0.05 | (0.49) | (0.70) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 24.98 | 22.00 | 13.20 | 14.46 | 19.54 | 15.21 | 8.42 |
| Revenue growth | +13.6% | +66.7% | -8.7% | -26.0% | +28.5% | +80.6% | - |
| EBITDA | 1.46 | 3.52 | (1.20) | 1.60 | 6.37 | 3.52 | (1.84) |
| EBITDA margin | +5.8% | +16.0% | -9.1% | +11.1% | +32.6% | +23.1% | -21.9% |
| Profit before tax | 0.05 | 2.07 | (2.69) | (0.09) | 4.45 | 1.39 | (4.22) |
| Net profit | 0.05 | 2.10 | (2.69) | (0.09) | 4.45 | 1.39 | (4.25) |
| Net profit margin | +0.2% | +9.6% | -20.4% | -0.6% | +22.8% | +9.1% | -50.5% |
| EPS (₹) | 0.05 | 2.01 | (2.60) | (0.09) | 4.33 | 1.34 | (4.56) |
| Balance sheet | |||||||
| Total assets | 16.27 | 15.97 | 13.34 | 16.43 | 16.99 | 10.60 | 12.90 |
| Net worth | 13.58 | 13.42 | 11.22 | 13.71 | 13.65 | 9.08 | 4.49 |
| Total debt | 1.97 | 1.99 | 1.70 | 2.35 | 3.06 | 1.31 | 8.19 |
| Cash & bank | 1.68 | 2.14 | 1.38 | 2.35 | 1.64 | 1.19 | 1.10 |
| Net working capital | 2.35 | 3.81 | 2.98 | 4.95 | 5.99 | 2.70 | 1.85 |
| Cash flow | |||||||
| Cash from operations | 1.45 | 1.88 | 1.05 | (0.01) | 2.03 | 5.67 | (1.87) |
| Cash from investing | (0.80) | 0.07 | 0.14 | 0.16 | (0.51) | (0.09) | 0.24 |
| Cash from financing | (1.14) | (0.99) | (0.95) | (0.94) | (1.35) | (2.17) | 1.27 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.26 | 6.17 | 6.52 | 5.12 | 8.09 | 5.25 | 5.78 | 5.41 |
| Revenue growth (YoY) | -22.6% | +17.5% | +12.8% | -5.4% | +30.9% | +13.2% | - | - |
| Other income | 0.09 | 0.12 | 0.14 | 0.13 | 0.14 | 0.11 | 0.13 | 0.09 |
| Total expenses | 6.94 | 5.83 | 6.86 | 6.33 | 5.90 | 4.43 | 4.72 | 4.64 |
| EBITDA | (0.68) | 0.34 | (0.34) | (1.21) | 2.19 | 0.82 | 1.06 | 0.77 |
| EBITDA margin | -10.9% | +5.5% | -5.2% | -23.6% | +27.1% | +15.6% | +18.3% | +14.2% |
| Depreciation | 0.46 | 0.41 | 0.40 | 0.38 | 0.40 | 0.37 | 0.37 | 0.39 |
| Interest | 0.11 | 0.09 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 |
| Profit before tax | (1.16) | (0.04) | (0.70) | (1.56) | 1.83 | 0.47 | 0.73 | 0.38 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Jun 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.25 | 5.78 | 5.41 | 6.18 | 4.64 | 3.82 | 2.60 |
| Revenue growth (YoY) | +13.2% | +51.3% | - | - | +78.5% | - | - |
| Other income | 0.11 | 0.13 | 0.09 | 0.08 | 0.16 | 0.08 | 0.10 |
| EBITDA | 0.68 | 0.92 | 0.61 | 1.28 | 0.27 | (0.20) | (0.43) |
| EBITDA margin | +13.0% | +15.9% | +11.3% | +20.7% | +5.8% | -5.2% | -16.5% |
| Depreciation | 0.37 | 0.37 | 0.39 | 0.36 | 0.38 | 0.38 | 0.39 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| EPS (₹) | 0.41 | 0.66 | 0.30 | 0.96 | 0.05 | (0.49) | (0.70) |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Revenue | 22.00 | 13.20 |
| Revenue growth | +66.7% | - |
| Other income | 0.39 | 0.42 |
| Total expenses | 18.53 | 14.40 |
| Employee cost | 7.33 | 6.20 |
| EBITDA | 3.47 | (1.20) |
| EBITDA margin | +15.8% | -9.1% |
| Depreciation | 1.49 | 1.54 |
| Interest | 0.35 | 0.37 |
| Profit before tax | 2.02 | (2.69) |
| Tax | 0.00 | 0.00 |
| Net profit | 2.05 | (2.69) |
| Net profit margin | +9.3% | -20.4% |
| EPS (₹) | 1.97 | (2.60) |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 16.43 | 16.30 |
| Reserves & surplus | (3.06) | (5.08) |
| Shareholders' funds (net worth) | 13.37 | 11.22 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 |
| Unsecured loans | 1.99 | 1.70 |
| Total debt | 1.99 | 1.70 |
| Total liabilities | 15.92 | 13.34 |
| Assets | ||
| Gross block | 18.31 | 17.20 |
| Net block | 6.53 | 6.79 |
| Capital work in progress | 0.00 | 0.00 |
| Investments | 0.08 | 0.00 |
| Inventories | 0.51 | 0.45 |
| Sundry debtors | 2.35 | 2.24 |
| Cash & bank balances | 2.14 | 1.38 |
| Loans & advances | 0.36 | 0.28 |
| Total current assets | 5.36 | 4.35 |
| Total current liabilities | 1.55 | 1.37 |
| Net working capital | 3.81 | 2.98 |
| Total assets | 15.92 | 13.34 |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Opening cash | 0.80 | 0.57 |
| Net cash from operating activities | 1.83 | 1.05 |
| Net cash from investing activities | 0.12 | 0.14 |
| Net cash from financing activities | (0.99) | (0.95) |
| Net change in cash | 0.95 | 0.24 |
| Closing cash | 2.14 | 1.38 |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Growth | ||
| Sales growth | +66.7% | - |
| EBITDA growth | +389.2% | - |
| PBT growth | +9998.0% | +9997.0% |
| Net income growth | +176.2% | - |
| Profitability & leverage | ||
| Net income margin | +9.2% | -20.4% |
| Return on capital employed | +11.5% | 0.0% |
| Return on net worth | +16.5% | 0.0% |
| Debt / equity | 0.15 | 0.15 |
| Long-term debt / equity | 0.09 | 0.09 |
| Interest cover | 17.68 | -13.50 |
| Efficiency & per share | ||
| Fixed asset turnover | 1.24 | 0.77 |
| Inventory turnover | 45.83 | 29.33 |
| Debtors turnover | 9.59 | 5.89 |
| EPS (₹) | 1.97 | (2.60) |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 7.03 | 5.07 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.26 | 6.17 | 6.52 | 5.12 | 8.09 | 5.25 | 5.78 | 5.41 |
| Revenue growth (YoY) | -22.6% | +17.5% | +12.8% | -5.4% | +30.9% | +13.2% | - | - |
| Other income | 0.09 | 0.12 | 0.14 | 0.13 | 0.14 | 0.11 | 0.13 | 0.09 |
| Total expenses | 6.94 | 5.83 | 6.86 | 6.33 | 5.90 | 4.43 | 4.72 | 4.64 |
| EBITDA | (0.68) | 0.34 | (0.34) | (1.21) | 2.19 | 0.82 | 1.06 | 0.77 |
| EBITDA margin | -10.9% | +5.5% | -5.2% | -23.6% | +27.1% | +15.6% | +18.3% | +14.2% |
| Depreciation | 0.46 | 0.41 | 0.40 | 0.38 | 0.40 | 0.37 | 0.37 | 0.39 |
| Interest | 0.11 | 0.09 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 |
| Profit before tax | (1.16) | (0.04) | (0.70) | (1.56) | 1.83 | 0.47 | 0.73 | 0.38 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 24.98 | 22.00 | 13.20 | 14.46 | 19.54 | 15.21 | 8.42 |
| Revenue growth | +13.6% | +66.7% | -8.7% | -26.0% | +28.5% | +80.6% | - |
| Other income | 0.52 | 0.39 | 0.42 | 0.32 | 0.09 | 0.20 | 0.29 |
| Total expenses | 23.52 | 18.48 | 14.40 | 12.86 | 13.17 | 11.69 | 10.26 |
| Employee cost | 0.00 | 7.33 | 6.20 | 5.59 | 5.02 | 4.03 | 4.95 |
| EBITDA | 1.46 | 3.52 | (1.20) | 1.60 | 6.37 | 3.52 | (1.84) |
| EBITDA margin | +5.8% | +16.0% | -9.1% | +11.1% | +32.6% | +23.1% | -21.9% |
| Depreciation | 1.54 | 1.49 | 1.54 | 1.59 | 1.64 | 1.44 | 1.66 |
| Interest | 0.39 | 0.35 | 0.37 | 0.42 | 0.37 | 0.89 | 1.01 |
| Profit before tax | 0.05 | 2.07 | (2.69) | (0.09) | 4.45 | 1.39 | (4.22) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Net profit | 0.05 | 2.10 | (2.69) | (0.09) | 4.45 | 1.39 | (4.25) |
| Net profit margin | +0.2% | +9.6% | -20.4% | -0.6% | +22.8% | +9.1% | -50.5% |
| EPS (₹) | 0.05 | 2.01 | (2.60) | (0.09) | 4.33 | 1.34 | (4.56) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.57 | 16.43 | 16.30 | 16.18 | 16.08 | 15.99 | 14.91 |
| Reserves & surplus | (2.99) | (3.01) | (5.08) | (2.47) | (2.43) | (6.91) | (10.42) |
| Shareholders' funds (net worth) | 13.58 | 13.42 | 11.22 | 13.71 | 13.65 | 9.08 | 4.49 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 4.91 |
| Unsecured loans | 1.97 | 1.99 | 1.70 | 2.35 | 3.06 | 0.83 | 3.28 |
| Total debt | 1.97 | 1.99 | 1.70 | 2.35 | 3.06 | 1.31 | 8.19 |
| Total liabilities | 16.27 | 15.97 | 13.34 | 16.43 | 16.99 | 10.60 | 12.90 |
| Assets | |||||||
| Gross block | 20.54 | 18.31 | 17.20 | 16.88 | 16.87 | 13.41 | 12.91 |
| Net block | 7.21 | 6.53 | 6.79 | 8.00 | 9.58 | 7.75 | 8.70 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.70 | 0.51 | 0.45 | 0.40 | 0.40 | 0.37 | 0.28 |
| Sundry debtors | 1.73 | 2.35 | 2.24 | 2.34 | 4.49 | 1.70 | 0.60 |
| Cash & bank balances | 1.68 | 2.14 | 1.38 | 2.35 | 1.64 | 1.19 | 1.10 |
| Loans & advances | 0.47 | 0.36 | 0.28 | 0.77 | 0.60 | 0.62 | 1.31 |
| Total current assets | 4.58 | 5.36 | 4.35 | 5.86 | 7.13 | 3.88 | 3.29 |
| Total current liabilities | 2.23 | 1.55 | 1.37 | 0.91 | 1.14 | 1.18 | 1.44 |
| Net working capital | 2.35 | 3.81 | 2.98 | 4.95 | 5.99 | 2.70 | 1.85 |
| Total assets | 16.27 | 15.97 | 13.34 | 16.43 | 16.99 | 10.60 | 12.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.75 | 0.80 | 0.57 | 1.35 | 1.19 | (2.22) | (1.87) |
| Net cash from operating activities | 1.45 | 1.88 | 1.05 | (0.01) | 2.03 | 5.67 | (1.87) |
| Net cash from investing activities | (0.80) | 0.07 | 0.14 | 0.16 | (0.51) | (0.09) | 0.24 |
| Net cash from financing activities | (1.14) | (0.99) | (0.95) | (0.94) | (1.35) | (2.17) | 1.27 |
| Net change in cash | (0.49) | 0.95 | 0.24 | (0.79) | 0.17 | 3.41 | (0.35) |
| Closing cash | 1.68 | 2.14 | 1.38 | 2.35 | 1.64 | 1.19 | 1.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +13.6% | +66.7% | -8.7% | -26.0% | +28.5% | +80.6% | - |
| EBITDA growth | -58.5% | +393.3% | -175.0% | -74.9% | +81.0% | +291.3% | - |
| PBT growth | -97.6% | +9998.0% | -2888.9% | - | +220.1% | +9998.0% | +18.5% |
| Net income growth | -97.6% | +178.1% | -2888.9% | -102.0% | +220.1% | +132.7% | - |
| Revenue CAGR (3Y) | +20.0% | +4.0% | -4.6% | +19.8% | +36.8% | +51.7% | +122.9% |
| EBITDA CAGR (3Y) | -3.0% | -17.9% | - | - | - | - | -10.5% |
| Profitability & leverage | |||||||
| Net income margin | +0.2% | +9.4% | -20.4% | -0.6% | +22.8% | +9.1% | -50.5% |
| Return on capital employed | +1.6% | +11.7% | 0.0% | 0.0% | +17.6% | +11.5% | 0.0% |
| Return on net worth | +0.3% | +16.9% | 0.0% | 0.0% | +23.1% | +15.2% | 0.0% |
| Debt / equity | 0.15 | 0.15 | 0.16 | 0.20 | 0.19 | 0.70 | 1.47 |
| Long-term debt / equity | 0.08 | 0.09 | 0.11 | 0.15 | 0.13 | 0.37 | 0.84 |
| Interest cover | -487.50 | 17.24 | -13.50 | 4,200.00 | 7.82 | 42.79 | -28.86 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.29 | 1.24 | 0.77 | 0.86 | 1.29 | 1.16 | 0.69 |
| Inventory turnover | 41.29 | 45.83 | 31.06 | 36.15 | 50.75 | 46.80 | 30.07 |
| Debtors turnover | 12.25 | 9.59 | 5.76 | 4.23 | 6.31 | 13.23 | 12.03 |
| EPS (₹) | 0.05 | 2.01 | (2.60) | (0.09) | 4.33 | 1.34 | (4.56) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 7.09 | 7.08 | 5.07 | 7.60 | 7.64 | 3.29 | (1.21) |
Timeline of Aspira Diagnostics
3 dated milestones of Aspira Diagnostics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Aspira Diagnostics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $401K.
Similar companies to Aspira Diagnostics
Aspira Diagnostics has 3 listed similar companies in our database, 3 of them funded. They include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lalpathlabs.com | 1949 | Gurugram, India | $13.9M | 8,279 | Chain of pathology and radiology labs | |
| redcliffelabs.com | 2018 | Noida, India | $116.42M | 2,104 | Home-based diagnostic tests are booked via an online platform. | |
| sterlingaccuris.com | 2015 | Ahmedabad, India | $41.69M | 1,229 | Pathology diagnostic services are offered via a chain of labs. |
Detailed similar companies of Aspira Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aspira Diagnostics
The website of Aspira Diagnostics (aspiradiagnostics.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 14% vs previous month
Top companies in Diagnostics Laboratories
3 companies that operate in the same segment as Aspira Diagnostics (Diagnostics Laboratories) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Diagnostic testing centers for pathology and health screenings are operated. | 1996 | Mumbai, Maharashtra, India | USD 63.59 M | USD 90.17 M | 1,979 | |
Chain of pathology and radiology labs | 1949 | Gurugram, Haryana, India | USD 13.9 M | USD 294.49 M | 5,310 | |
Home-based diagnostic tests are booked via an online platform. | 2018 | Noida, Uttar Pradesh, India | USD 116.42 M | USD 52.45 M | 2,334 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aspira Diagnostics
Complete news archive for Aspira Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aspira Diagnostics
Aspira Diagnostics was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Aspira Diagnostics is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Chander Puri is the CEO of Aspira Diagnostics, as recorded in our data.
Aspira Diagnostics has 70 employees.
The primary company behind Aspira Diagnostics, Aspira Pathlab & Diagnostics Limited, reported revenue of ₹25.50 Cr for FY 2026, up 14% year on year.
Aspira was founded in 2015 and is based in Mumbai, India. The company operates as a chain of pathology labs focused on diagnostic services. Core activities include laboratory testing and pathology diagnostics, with operations centered in the healthcare sector. The domain aspiradiagnostics.com is used for its online presence. Leadership is provided by CEO Chander Puri.
Aspira Diagnostics's top competitors include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.
Aspira Diagnostics offers Pathology Test, Sonography, X-Ray, and Health Packages.
Yes, Aspira Diagnostics is publicly traded on BSE under the ticker symbol ASPIRA.
Aspira Diagnostics operates through Aspira Pathlab & Diagnostics Limited.
The legal entities of Aspira Diagnostics currently have 9 directors, including Manas Rajendra Mengar, Vaibhav Odhekar, Kiran Raghavendra Awasthi and others.
